Jason Paragas

1 month ago | statnews.com | Ellen P. Carlin |Jason Paragas

The Food and Drug Administration’s recent decision to phase out animal use in preclinical testing of monoclonal antibodies — and eventually other drugs —with more advanced, human-relevant methods marks a transformative shift with profound implications for drug development. The FDA has now officially recognized that advancing science and technology have pushed us across a threshold: Animal models have become obsolete.